Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Emily Bodnar

In-Depth Examination Of 14 Analyst Recommendations For Arcellx

In the last three months, 14 analysts have published ratings on Arcellx (NASDAQ:ACLX), offering a diverse range of perspectives from bullish to bearish.

Benzinga · Dec 9, 2024

14 Analysts Have This To Say About Arcellx

In the latest quarter, 14 analysts provided ratings for Arcellx (NASDAQ:ACLX), showcasing a mix of bullish and bearish perspectives.

Benzinga · Dec 9, 2024

Key Takeaways From AnaptysBio Analyst Ratings

Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on AnaptysBio (NASDAQ:ANAB) in the last three months.

Benzinga · Dec 2, 2024

From analysis to the latest developments in health,
read the most diverse news in one place.

Navigating 5 Analyst Ratings For NovoCure

5 analysts have shared their evaluations of NovoCure (NASDAQ:NVCR) during the recent three months, expressing a mix of bullish and bearish perspectives.

Benzinga · Dec 2, 2024

The Latest Analyst Ratings For Femasys

During the last three months, 5 analysts shared their evaluations of Femasys (NASDAQ:FEMY), revealing diverse outlooks from bullish to bearish.

Benzinga · Nov 27, 2024

2 Penny Stocks That Wall Street Believes Can Soar Around 292% to 442%

Analysts believe these two penny stocks have outstanding long-term potential.

Barchart · Aug 28, 2024

Coverage From

People

Vijay Kumar

141 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.